Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female participants aged 18 to 49 years of age at the time of enrollment.~2. Are in good health at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator.~3. Participants with a signed informed consent form and any required privacy authorization prior to the initiation of any trial procedures and after the nature of the trial has been explained according to local regulatory requirements.~4. Can comply with trial procedures and are available for the duration of the trial.~Exclusion Criteria:~1. Has a history of acute gastroenteritis within 14 days of enrollment.~2. Has a clinically significant active infection (as assessed by the investigator) or oral body temperature 38°C (100.4°F) or higher within 3 days of the intended date of vaccination.~3. Has received antipyretic/analgesic medications within 24 hours prior to the intended vaccine administration.~4. Has known hypersensitivity or allergy to any of the bivalent norovirus virus-like particle (VLP) vaccine components (including excipients of the investigational vaccines).~5. Has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.~6. Has a history of any progressive or severe neurologic disorder, seizure disorder, or neuro-inflammatory disease (e.g., Guillain-Barré syndrome).~7. Has history or any illness that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the participants due to participation in the trial.~8. Has known or suspected impairment/alteration of immune function including the following:~   1. Chronic use of oral steroids (Equivalent to 20 mg/day prednisone for ≥ 12 weeks / ≥2 mg/kg body weight /day for ≥ 2 weeks) within 60 days prior to Day 1 (use of inhaled, intranasal, or topical corticosteroids is allowed).~  2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥ 12 weeks / ≥2 mg/kg body weight /day for ≥2 weeks) within 60 days prior to Day 1.~  3. Receipt of immunostimulants within 60 days prior to Day 1.~  4. Receipt of parenteral, epidural, or intra-articular immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Day 1 or planned during the full length of the trial.~  5. Receipt of immunosuppressive therapy within 6 months prior to Day 1.~  6. Human immunodeficiency virus (HIV) infection or HIV-related disease.~  7. Heritable immunodeficiency.~9. Has abnormalities of splenic or thymic function.~10. Has a history of any autoimmune disease.~11. Has a known bleeding diathesis or any condition that may be associated with a prolonged bleeding time.~12. Has any serious chronic or progressive disease according to judgment of the investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal, or hepatic disease).~13. Has a body mass index (BMI) greater than or equal to 35 kg/m\^2 (= weight in kg / \[height in meters \* height in meters\]).~14. Is participating in any clinical trial with another investigational product 30 days prior to first trial visit or intent to participate in another clinical trial at any time during the conduct of this trial.~15. Participants who received any inactivated vaccines within 14 days or any live vaccines for 28 days prior to enrollment in this trial.~16. Are first degree relatives of individuals involved in trial conduct.~17. Has a history of substance or alcohol abuse within the past 2 years.~18. If female, of childbearing potential, sexually active, and has not used any of the acceptable contraceptive methods for at least 2 months prior to trial entry:~    1. Of childbearing potential is defined as status post onset of menarche and not meeting any of the following conditions: menopausal for at least 2 years, status after bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or status after hysterectomy.~   2. Acceptable birth control methods are defined as 1 or more of the following:~    i. Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring).~    ii. Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse.~    iii. Intrauterine device (IUD). iv. Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least 6 months prior to the participant's trial entry.~19. Female participants of childbearing potential and sexually active, who refuse to use an acceptable contraceptive method from Day 1 through 6 months after the last dose of investigational vaccine.~20. Female participants who plan to donate ova from Day 1 through 6 months after the last dose of investigational vaccine.~21. Female participants with any positive pregnancy test.~22. Female participants who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) (Type: EXPERIMENTAL): Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
- GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) (Type: EXPERIMENTAL): IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
- Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) (Type: PLACEBO_COMPARATOR): IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.

Based on this trial design, predict the completion outcome and termination type (if applicable).